<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04532424</url>
  </required_header>
  <id_info>
    <org_study_id>57738</org_study_id>
    <nct_id>NCT04532424</nct_id>
  </id_info>
  <brief_title>Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD</brief_title>
  <acronym>TMS for ASD</acronym>
  <official_title>Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigating the efficacy of a form of TMS called theta-burst stimulation for restricted and&#xD;
      repetitive behavior in ASD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Recruitment is currently suspended due to a change in PI and staff training is required.&#xD;
  </why_stopped>
  <start_date type="Actual">January 4, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be assigned to one of 2 groups based on the presentation of restricted and repetitive behavior.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Repetitive Behavior Scale-Revised (RBS-R)</measure>
    <time_frame>Up to one month post-treatment</time_frame>
    <description>44-item parent-report questionnaire to measure restricted and repetitive behavior in ASD. We predict that each TMS target will selectively reduce the subscale being targeted.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Set-shifting performance (Dimensional Change Card Sort Test score)</measure>
    <time_frame>Baseline &amp; immediately after treatment</time_frame>
    <description>The Dimensional Change Card Sort Test one of the cognitive measures from the NIH toolbox. These measures are administered on an iPad. The test takes 4 minutes to complete.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <condition>Autism</condition>
  <condition>Asperger Syndrome</condition>
  <arm_group>
    <arm_group_label>Targeting insistence on sameness</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Targeting stereotyped motor behaviors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial magnetic stimulation</intervention_name>
    <description>Non-invasive brain stimulation technique that is FDA-approved for the treatment of refractory depression, OCD and migraine.</description>
    <arm_group_label>Targeting insistence on sameness</arm_group_label>
    <arm_group_label>Targeting stereotyped motor behaviors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of Autism Spectrum Disorder (ASD), Asperger's or Autism.&#xD;
&#xD;
          2. Meet criteria for ASD on clinical assessments (ADOS-2 or CARS/BOSA if conducted&#xD;
             remotely &amp; ADI-R)&#xD;
&#xD;
          3. Aged between 12-45 years old&#xD;
&#xD;
          4. Have a reliable informant who can complete relevant questionnaires&#xD;
&#xD;
          5. Must have previously not responded or not tolerated 2 treatments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any contraindications for TMS e.g. history of seizures&#xD;
&#xD;
          2. Pregnancy&#xD;
&#xD;
          3. Any current or past history of any physical condition which in the investigator's&#xD;
             opinion might put the subject at risk or interfere with study results interpretation.&#xD;
&#xD;
          4. Active substance use (&lt;1 week) or intoxication verified by toxicology screen--of&#xD;
             cocaine, amphetamines, benzodiazepines&#xD;
&#xD;
          5. Showing symptoms of withdrawal from alcohol or benzodiazepines&#xD;
&#xD;
          6. DSM-5 diagnosis of bipolar disorder or a psychotic disorder e.g. schizophrenia.&#xD;
&#xD;
          7. Significant sensory impairments such as blindness or deafness.&#xD;
&#xD;
          8. Any other indication the PI feels would comprise data&#xD;
&#xD;
          9. Current severe insomnia (must sleep a minimum of 4 hours the night before stimulation)&#xD;
&#xD;
         10. IQ&lt;50 or not testable using IQ measures and no historical IQ score available&#xD;
&#xD;
         11. Currently taking Clozapine or another medication that the PI determines increases the&#xD;
             risk of TMS or may disrupt the efficacy.&#xD;
&#xD;
         12. A motor threshold that is too high to allow safe/tolerable treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Y. Hardan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robin Libove</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Barahona-CorrÃªa JB, Velosa A, Chainho A, Lopes R, Oliveira-Maia AJ. Repetitive Transcranial Magnetic Stimulation for Treatment of Autism Spectrum Disorder: A Systematic Review and Meta-Analysis. Front Integr Neurosci. 2018 Jul 9;12:27. doi: 10.3389/fnint.2018.00027. eCollection 2018.</citation>
    <PMID>30038561</PMID>
  </reference>
  <reference>
    <citation>Oberman LM, Rotenberg A, Pascual-Leone A. Use of transcranial magnetic stimulation in autism spectrum disorders. J Autism Dev Disord. 2015 Feb;45(2):524-36. doi: 10.1007/s10803-013-1960-2. Review.</citation>
    <PMID>24127165</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Antonio Hardan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Asperger Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

